Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|Humanized Influenza Monoclonal Antibodies (SJ-07-0004)|
|Description||Highly pathogenic avian H5N1 influenza virus is a major public health concern. Given the lack of effective vaccine and recent evidence of antiviral drug resistance in some isolates, alternative strategies for containment of a possible future pandemic are needed. Humanized monoclonal antibodies (mAbs) that neutralize H5N1 virus could be used as prophylaxis and treatment to aid in the containment of such a pandemic.
Investigators from St. Jude Children's Research Hospital and DSO National Laboratories, Singapore developed two neutralizing humanized monoclonal antibodies. One against H5 hemagglutinin from A/Vietnam/1204/05 and the other against A/HongKong/213/03. Both antibodies retained specificity and exhibited prophylactic efficacy in mice.
Studies with these antibodies show passive antibody therapy can be an effective tool for both prophylaxis against- and treatment of- highly pathogenic H5N1 influenza virus, providing the immediate immunity needed which combined with social distancing could limit the transmission of H5N1 virus to others and contain a future influenza pandemic.
|Keywords||Influenza monoclonal antibody, influenza prophylactic, influenza treatment|
|Granted Patents or Published Applications||Singapore Patent No. 149,928; pending U.S. Application published June 17, 2010 as US 2010/0150941|
|Related Scientific References||Hanson, Brendon J., et.al, Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res. 2006; 7(1): 126.|
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2010